Abstract: A cDNA encoding a novel LTC4 receptor has been isolated. Provision of the novel protein, an LTC4 receptor, enabled binding experiments using the LTC4. By screening for compounds that modulate LTC4 receptor activity based on these binding experiments, development of drugs targeting the LTC4 receptor becomes possible.
Type:
Grant
Filed:
September 2, 2004
Date of Patent:
May 15, 2007
Assignees:
Astellas Pharma Inc., Helix Research Institute
Abstract: A cDNA encoding a novel LTC4 receptor has been isolated. Provision of the novel protein, an LTC4 receptor, enabled binding experiments using the LTC4. By screening for compounds that modulate LTC4 receptor activity based on these binding experiments, development of drugs targeting the LTC4 receptor becomes possible.
Type:
Grant
Filed:
September 13, 2000
Date of Patent:
April 12, 2005
Assignees:
Yamanouchi Pharmaceutical Co, Ltd., Helix Research Institute
Abstract: The object of the present invention is to provide an amino acid frame indication system, a method for amino acid frame indication and a recording medium, which can effectively extract a highly reliable amino acid sequence from a cDNA sequence, even in a case where there exists a frame shift error in the cDNA sequence.
Type:
Application
Filed:
August 29, 2001
Publication date:
April 25, 2002
Applicant:
Hitachi, Ltd. and Helix Research Institute
Abstract: A mouse CDNA encoding a protein comprising a serine/threonine protein kinase region was isolated by effecting PCR using a synthetic DNA corresponding to the kinase-conserved region as a primer and a rat cDNA as a template. A mouse cDNA library was screened using the DNA fragment thus obtained as a probe. The multiple human and mouse cDNAs having the similar structure to the isolated mouse cDNA were successfully isolated based on the sequence of the isolated mouse cDNA. An antisense DNA against the isolated mouse cDNA was synthesized, and its effect on a nerve cell was studied to confirm that the antisense DNA inhibits axonal elongation.
© 2024 Justia
